Increased expression of miR-34a in mouse spleen one day after exposure to N-ethyl-N-nitrosourea

Journal of Applied Toxicology

Volumn 31, Issue 5, 2011, Pages 496-498

  Chen, David ^a   Li, Zhiguang ^b   Chen, Tao ^b  

^a Little Rock Central High School   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

MiR 34a; Mutagen; N ethyl N nitrosourea; p53; Real time PCR

Indexed keywords

ETHYLNITROSOUREA; MICRORNA; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENOTOXICITY; MOUSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN;

ALKYLATING AGENTS; ANIMALS; CARCINOGENS; ETHYLNITROSOUREA; FEMALE; GENE EXPRESSION; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICRORNAS; SPLEEN; TIME FACTORS;

MUS;

EID: 79960739349     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1640     Document Type: Article

References (29)

1. Ambros V. 2003. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113: 673-676.
2. Bhatti I, Lee A, Lund J, Larvin M. 2009. Small RNA: a large contributor to carcinogenesis? J. Gastrointest. Surg. 13: 1379-1388.
3. Bronstein SM, Skopek TR, Swenberg JA. 1992. Efficient repair of O6-ethylguanine, but not O4-ethylthymine or O2-ethylthymine, is dependent upon O6-alkylguanine-DNA alkyltransferase and nucleotide excision repair activities in human cells. Cancer Res. 52: 2008-2011.
4. Budan F, Varjas T, Nowrasteh G, Prantner I, Varga Z, Ember A, Cseh J, Gombos K, Pazsit E, Gobel G, Bauer M, Gracza T, Arany I, Perjesi P, Ember I, Kiss I. 2009. Early modification of c-myc, Ha-ras and p53 expressions by chemical carcinogens (DMBA, MNU). In Vivo 23: 591-598.
5. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. 2007. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26: 745-752.
6. Chen T. 2010. The role of MicroRNA in chemical carcinogenesis. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 28: 89-124.
7. Churchwell MI, Beland FA, Doerge DR. 2006. Quantification of O6-methyl and O6-ethyl deoxyguanosine adducts in C57BL/6N/Tk+/- mice using LC/MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 844: 60-66.
8. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, Nikitin AY. 2010. Frequent downregulation of miR-34 family in human ovarian cancers. Clin. Cancer Res. 16: 1119-1128.
9. Cummins JM, Velculescu VE. 2006. Implications of micro-RNA profiling for cancer diagnosis. Oncogene 25: 6220-6227.
10. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, Liu CG, Volinia S, Croce CM, Schmittgen TD, Ghoshal K, Jacob ST. 2008. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 68: 5049-5058.
11. Davidson LA, Wang N, Shah MS, Lupton JR, Ivanov I, Chapkin RS. 2009. n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis 30: 2077-2084.
12. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez J, Monzo M. 2009. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30: 1903-1909.
13. Hagan JP, Croce CM. 2007. MicroRNAs in carcinogenesis. Cytogenet. Genome Res. 118: 252-259.
14. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, Jr. 2007. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25: 5287-5312.
15. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134.
16. Hermeking H. 2009. MiR-34a and p53. Cell Cycle 8: 1308.
17. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. 2005. MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
18. Mott JL. 2009. MicroRNAs involved in tumor suppressor and oncogene pathways: implications for hepatobiliary neoplasia. Hepatology 50: 630-637.
19. Osada H, Takahashi T. 2007. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 28: 2-12.
20. Pogribny IP, Muskhelishvili L, Tryndyak VP, Beland FA. 2009. The tumor-promoting activity of 2-acetylaminofluorene is associated with disruption of the p53 signaling pathway and the balance between apoptosis and cell proliferation. Toxicol. Appl. Pharmacol. 235: 305-311.
21. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB. 2008. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol. Ther. 7: 1288-1296.
22. Schwartz D, Rotter V. 1998. p53-dependent cell cycle control: response to genotoxic stress. Semin. Cancer Biol. 8: 325-336.
23. Shackelford RE, Kaufmann WK, Paules RS. 1999. Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ. Health Perspect. 107(suppl. 1): 5-24.
24. Shivdasani RA. 2006. MicroRNAs: regulators of gene expression and cell differentiation. Blood 108: 3646-3653.
25. Tryndyak VP, Ross SA, Beland FA, Pogribny IP. 2009. Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Mol. Carcinog. 48: 479-487.
26. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103: 2257-2261.
27. Wallace-Brodeur RR, Lowe SW. 1999. Clinical implications of p53 mutations. Cell Mol. Life Sci. 55: 64-75.
28. Wang JY, Liu XL, Heflich RH, Chen T. 2004. Time course of cII gene mutant manifestation in the liver, spleen, and bone marrow of N-ethyl-N-nitrosourea-treated big blue transgenic mice. Toxicol. Sci. 82: 124-128.
29. Yamakuchi M, Lowenstein CJ. 2009. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 8: 712-715.